All In Biotech

Drug Trial Radar · NCT05318521

RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee

A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product "Ibuprofen Modified-Release Tablets 800 mg" and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 10, 2021

Primary completion

Aug 12, 2022

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Overseas Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
Collaborators
Virginia Contract Research Organization Co., Ltd.
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a Phase III efficacy study as the title 'A randomized, double-blind, parallel-arm study comparing the efficacy of investigational product "Ibuprofen Modified-Release Tablets 800 mg" and placebo in patients with chronic pain related to osteoarthritis of the knee.' The primary objective is to determine the analgesic efficacy of orally administered IBUMR in patients with osteoarthritis (OA) of the knee. The Secondary objectives are to compare the treatment effect on patient pain, function and stiffness between IBUMR- and placebo-treated patients as measured by the Western Ontario and McMaster Osteoarthritis Index (WOMAC), to compare the treatment effect on Patient Global Assessment on Disease Activity between IBUMR- and placebo-treated patients, to compare the treatment effect on Investigator's Global Assessment on Disease Activity between IBUMR- and placebo-treated patients, to compare the use of analgesic rescue medicine between IBUMR- and placebo-treated patients, to determine the safety profile of IBUMR.

Conditions

  • Degenerative Arthritis

Interventions

  • PlaceboDrug

    The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen

  • Ibuprofen modified release tablet 800 mgDrug

    Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the WOMAC visual analogue 3.1 Pain intensity subscale, over 12 weeks of treatment. [Time frame: Baseline week up to Week 12]Time frame: at baseline week (Day -6 to Day 1) and at Day 8, 15, 22, 29, 43, 57 and Week 12 (Day 79 to Day 85).

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Core Healthcare

    Cerritos, California

  • National Institute of Clinical Research

    Garden Grove, California

  • Paragon Rx Clinical, Inc.

    Santa Ana, California

  • Well Pharma Medical Research

    Miami, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Cvillemedresearch

    Charlottesville, Virginia

  • Taipei Medical University Shuang Ho Hospital

    New Taipei City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Taipei Medical University Hospital

    Taipei, Taiwan

  • Taipei Municipal Wanfang Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.